APO Research
Talk to an analyst

APO RESEARCH · REPORT

Companion Animal Pharmaceutical

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Companion Animal Pharmaceutical Market Outlook and Growth Opportunities 2026

2 January 2026192 pages

Choose your research edition.

Industry ResearchCompanion Animal Pharmaceutical Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Companion Animal Pharmaceutical Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Companion Animal Pharmaceutical Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Companion Animal Pharmaceutical Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Companion Animal Pharmaceutical Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Companion Animal Pharmaceutical market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Companion Animal Pharmaceutical is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Companion Animal Pharmaceutical is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Companion Animal Pharmaceutical is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Companion Animal Pharmaceutical market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Companion Animal Pharmaceutical market include Boehringer Ingelheim, Ceva, Dechra Veterinary Products, Elanco Animal Health, Meiji, Ouro Fino Saude, Parnell, Vetoquinol and Virbac, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Companion Animal Pharmaceutical market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Companion Animal Pharmaceutical and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Companion Animal Pharmaceutical revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Companion Animal Pharmaceutical market.

Companion Animal Pharmaceutical Segment by Company

Boehringer Ingelheim

Ceva

Dechra Veterinary Products

Elanco Animal Health

Meiji

Ouro Fino Saude

Parnell

Vetoquinol

Virbac

Zoetis

Bayer Animal Health

Merck Animal Health

Companion Animal Pharmaceutical Segment by Type

Infectious Diseases

Orthopedic Diseases

Dermatologic Diseases

Pain

Behavioral Diseases

Other Indications

Companion Animal Pharmaceutical Segment by Application

Dogs

Cats

Other

Companion Animal Pharmaceutical Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Companion Animal Pharmaceutical status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Companion Animal Pharmaceutical key companies, revenue, market share, and recent developments.

3. To split the Companion Animal Pharmaceutical breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Companion Animal Pharmaceutical market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Companion Animal Pharmaceutical significant trends, drivers, influence factors in global and regions.

6. To analyze Companion Animal Pharmaceutical competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Companion Animal Pharmaceutical market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Companion Animal Pharmaceutical and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Companion Animal Pharmaceutical.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Companion Animal Pharmaceutical industry.

Chapter 3: Detailed analysis of Companion Animal Pharmaceutical company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Companion Animal Pharmaceutical in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Companion Animal Pharmaceutical in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Companion Animal Pharmaceutical Industry Trends Table 2. Companion Animal Pharmaceutical Industry Drivers Table 3. Companion Animal Pharmaceutical Industry Opportunities and Challenges Table 4. Companion Animal Pharmaceutical Industry Restraints Table 5. Global Companion Animal Pharmaceutical Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Companion Animal Pharmaceutical Revenue Share by Company (2021-2026) Table 7. Global Companion Animal Pharmaceutical Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Companion Animal Pharmaceutical Key Company Manufacturing Base & Headquarters Table 9. Global Companion Animal Pharmaceutical Company, Product Type & Application Table 10. Global Companion Animal Pharmaceutical Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Companion Animal Pharmaceutical by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Infectious Diseases Table 15. Significant Companies of Orthopedic Diseases Table 16. Significant Companies of Dermatologic Diseases Table 17. Significant Companies of Pain Table 18. Significant Companies of Behavioral Diseases Table 19. Significant Companies of Other Indications Table 20. Global Companion Animal Pharmaceutical Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 21. Global Companion Animal Pharmaceutical Sales Value by Type (2021-2026) & (US$ Million) Table 22. Global Companion Animal Pharmaceutical Sales Value by Type (2027-2032) & (US$ Million) Table 23. Global Companion Animal Pharmaceutical Sales Value Share by Type (2021-2026) Table 24. Global Companion Animal Pharmaceutical Sales Value Share by Type (2027-2032) Table 25. Significant Companies of Dogs Table 26. Significant Companies of Cats Table 27. Significant Companies of Other Table 28. Global Companion Animal Pharmaceutical Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Companion Animal Pharmaceutical Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global Companion Animal Pharmaceutical Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global Companion Animal Pharmaceutical Sales Value Share by Application (2021-2026) Table 32. Global Companion Animal Pharmaceutical Sales Value Share by Application (2027-2032) Table 33. Global Companion Animal Pharmaceutical Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Companion Animal Pharmaceutical Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global Companion Animal Pharmaceutical Sales Value Share by Region (2021-2026) Table 36. Global Companion Animal Pharmaceutical Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global Companion Animal Pharmaceutical Sales Value Share by Region (2027-2032) Table 38. Global Companion Animal Pharmaceutical Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Companion Animal Pharmaceutical Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global Companion Animal Pharmaceutical Sales Value Market Share by Country (2021-2026) Table 41. Global Companion Animal Pharmaceutical Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global Companion Animal Pharmaceutical Sales Value Market Share by Country (2027-2032) Table 43. Boehringer Ingelheim Company Information Table 44. Boehringer Ingelheim Business Overview Table 45. Boehringer Ingelheim Companion Animal Pharmaceutical Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Boehringer Ingelheim Companion Animal Pharmaceutical Product Portfolio Table 47. Boehringer Ingelheim Recent Development Table 48. Ceva Company Information Table 49. Ceva Business Overview Table 50. Ceva Companion Animal Pharmaceutical Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Ceva Companion Animal Pharmaceutical Product Portfolio Table 52. Ceva Recent Development Table 53. Dechra Veterinary Products Company Information Table 54. Dechra Veterinary Products Business Overview Table 55. Dechra Veterinary Products Companion Animal Pharmaceutical Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Dechra Veterinary Products Companion Animal Pharmaceutical Product Portfolio Table 57. Dechra Veterinary Products Recent Development Table 58. Elanco Animal Health Company Information Table 59. Elanco Animal Health Business Overview Table 60. Elanco Animal Health Companion Animal Pharmaceutical Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Elanco Animal Health Companion Animal Pharmaceutical Product Portfolio Table 62. Elanco Animal Health Recent Development Table 63. Meiji Company Information Table 64. Meiji Business Overview Table 65. Meiji Companion Animal Pharmaceutical Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Meiji Companion Animal Pharmaceutical Product Portfolio Table 67. Meiji Recent Development Table 68. Ouro Fino Saude Company Information Table 69. Ouro Fino Saude Business Overview Table 70. Ouro Fino Saude Companion Animal Pharmaceutical Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Ouro Fino Saude Companion Animal Pharmaceutical Product Portfolio Table 72. Ouro Fino Saude Recent Development Table 73. Parnell Company Information Table 74. Parnell Business Overview Table 75. Parnell Companion Animal Pharmaceutical Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Parnell Companion Animal Pharmaceutical Product Portfolio Table 77. Parnell Recent Development Table 78. Vetoquinol Company Information Table 79. Vetoquinol Business Overview Table 80. Vetoquinol Companion Animal Pharmaceutical Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Vetoquinol Companion Animal Pharmaceutical Product Portfolio Table 82. Vetoquinol Recent Development Table 83. Virbac Company Information Table 84. Virbac Business Overview Table 85. Virbac Companion Animal Pharmaceutical Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Virbac Companion Animal Pharmaceutical Product Portfolio Table 87. Virbac Recent Development Table 88. Zoetis Company Information Table 89. Zoetis Business Overview Table 90. Zoetis Companion Animal Pharmaceutical Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Zoetis Companion Animal Pharmaceutical Product Portfolio Table 92. Zoetis Recent Development Table 93. Bayer Animal Health Company Information Table 94. Bayer Animal Health Business Overview Table 95. Bayer Animal Health Companion Animal Pharmaceutical Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Bayer Animal Health Companion Animal Pharmaceutical Product Portfolio Table 97. Bayer Animal Health Recent Development Table 98. Merck Animal Health Company Information Table 99. Merck Animal Health Business Overview Table 100. Merck Animal Health Companion Animal Pharmaceutical Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Merck Animal Health Companion Animal Pharmaceutical Product Portfolio Table 102. Merck Animal Health Recent Development Table 103. Research Programs/Design for This Report Table 104. Authors List of This Report Table 105. Secondary Sources Table 106. Primary Sources List of Figures Figure 1. Companion Animal Pharmaceutical Product Image Figure 2. Global Companion Animal Pharmaceutical Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Companion Animal Pharmaceutical Market Size (2021-2032) & (US$ Million) Figure 4. Global Companion Animal Pharmaceutical Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Infectious Diseases Image Figure 8. Orthopedic Diseases Image Figure 9. Dermatologic Diseases Image Figure 10. Pain Image Figure 11. Behavioral Diseases Image Figure 12. Other Indications Image Figure 13. Global Companion Animal Pharmaceutical Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 14. Global Companion Animal Pharmaceutical Sales Value Share 2021 VS 2025 VS 2032 Figure 15. Global Companion Animal Pharmaceutical Sales Value Share by Type (2021-2032) Figure 16. Dogs Image Figure 17. Cats Image Figure 18. Other Image Figure 19. Global Companion Animal Pharmaceutical Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Companion Animal Pharmaceutical Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Companion Animal Pharmaceutical Sales Value Share by Application (2021-2032) Figure 22. Global Companion Animal Pharmaceutical Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global Companion Animal Pharmaceutical Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America Companion Animal Pharmaceutical Sales Value (2021-2032) & (US$ Million) Figure 25. North America Companion Animal Pharmaceutical Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe Companion Animal Pharmaceutical Sales Value (2021-2032) & (US$ Million) Figure 27. Europe Companion Animal Pharmaceutical Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific Companion Animal Pharmaceutical Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific Companion Animal Pharmaceutical Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America Companion Animal Pharmaceutical Sales Value (2021-2032) & (US$ Million) Figure 31. South America Companion Animal Pharmaceutical Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa Companion Animal Pharmaceutical Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa Companion Animal Pharmaceutical Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • Infectious Diseases
  • Orthopedic Diseases
  • Dermatologic Diseases
  • Pain
  • Behavioral Diseases
  • Other Indications
Applications
  • Dogs
  • Cats
  • Other
Companies covered
  • Boehringer Ingelheim
  • Ceva
  • Dechra Veterinary Products
  • Elanco Animal Health
  • Meiji
  • Ouro Fino Saude
  • Parnell
  • Vetoquinol
  • Virbac
  • Zoetis
  • Bayer Animal Health
  • Merck Animal Health

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Companion Animal Pharmaceutical Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Companion Animal Pharmaceutical Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Companion Animal Pharmaceutical Market Dynamics
  1. 2.1 Companion Animal Pharmaceutical Industry Trends
  2. 2.2 Companion Animal Pharmaceutical Industry Drivers
  3. 2.3 Companion Animal Pharmaceutical Industry Opportunities and Challenges
  4. 2.4 Companion Animal Pharmaceutical Industry Restraints
3 Companion Animal Pharmaceutical Market by Company
  1. 3.1 Global Companion Animal Pharmaceutical Company Revenue Ranking in 2025
  2. 3.2 Global Companion Animal Pharmaceutical Revenue by Company (2021-2026)
  3. 3.3 Global Companion Animal Pharmaceutical Company Ranking (2024-2026)
  4. 3.4 Global Companion Animal Pharmaceutical Company Manufacturing Base and Headquarters
  5. 3.5 Global Companion Animal Pharmaceutical Company Product Type and Application
  6. 3.6 Global Companion Animal Pharmaceutical Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Companion Animal Pharmaceutical Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Companion Animal Pharmaceutical Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Companion Animal Pharmaceutical Market by Type
  1. 4.1 Companion Animal Pharmaceutical Type Introduction
  2. 4.1.1 Infectious Diseases
  3. 4.1.2 Orthopedic Diseases
  4. 4.1.3 Dermatologic Diseases
  5. 4.1.4 Pain
  6. 4.1.5 Behavioral Diseases
  7. 4.1.6 Other Indications
  8. 4.2 Global Companion Animal Pharmaceutical Sales Value by Type
  9. 4.2.1 Global Companion Animal Pharmaceutical Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Companion Animal Pharmaceutical Sales Value by Type (2021-2032)
  11. 4.2.3 Global Companion Animal Pharmaceutical Sales Value Share by Type (2021-2032)
5 Companion Animal Pharmaceutical Market by Application
  1. 5.1 Companion Animal Pharmaceutical Application Introduction
  2. 5.1.1 Dogs
  3. 5.1.2 Cats
  4. 5.1.3 Other
  5. 5.2 Global Companion Animal Pharmaceutical Sales Value by Application
  6. 5.2.1 Global Companion Animal Pharmaceutical Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Companion Animal Pharmaceutical Sales Value by Application (2021-2032)
  8. 5.2.3 Global Companion Animal Pharmaceutical Sales Value Share by Application (2021-2032)
6 Companion Animal Pharmaceutical Regional Value Analysis
  1. 6.1 Global Companion Animal Pharmaceutical Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Companion Animal Pharmaceutical Sales Value by Region (2021-2032)
  3. 6.2.1 Global Companion Animal Pharmaceutical Sales Value by Region: 2021-2026
  4. 6.2.2 Global Companion Animal Pharmaceutical Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Companion Animal Pharmaceutical Sales Value (2021-2032)
  7. 6.3.2 North America Companion Animal Pharmaceutical Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Companion Animal Pharmaceutical Sales Value (2021-2032)
  10. 6.4.2 Europe Companion Animal Pharmaceutical Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Companion Animal Pharmaceutical Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Companion Animal Pharmaceutical Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Companion Animal Pharmaceutical Sales Value (2021-2032)
  16. 6.6.2 South America Companion Animal Pharmaceutical Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Companion Animal Pharmaceutical Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Companion Animal Pharmaceutical Sales Value Share by Country, 2025 VS 2032
7 Companion Animal Pharmaceutical Country-level Value Analysis
  1. 7.1 Global Companion Animal Pharmaceutical Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Companion Animal Pharmaceutical Sales Value by Country (2021-2032)
  3. 7.2.1 Global Companion Animal Pharmaceutical Sales Value by Country (2021-2026)
  4. 7.2.2 Global Companion Animal Pharmaceutical Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Companion Animal Pharmaceutical Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Companion Animal Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Companion Animal Pharmaceutical Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Boehringer Ingelheim
  2. 8.1.1 Boehringer Ingelheim Company Information
  3. 8.1.2 Boehringer Ingelheim Business Overview
  4. 8.1.3 Boehringer Ingelheim Companion Animal Pharmaceutical Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Boehringer Ingelheim Companion Animal Pharmaceutical Product Portfolio
  6. 8.1.5 Boehringer Ingelheim Recent Developments
  7. 8.2 Ceva
  8. 8.2.1 Ceva Company Information
  9. 8.2.2 Ceva Business Overview
  10. 8.2.3 Ceva Companion Animal Pharmaceutical Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Ceva Companion Animal Pharmaceutical Product Portfolio
  12. 8.2.5 Ceva Recent Developments
  13. 8.3 Dechra Veterinary Products
  14. 8.3.1 Dechra Veterinary Products Company Information
  15. 8.3.2 Dechra Veterinary Products Business Overview
  16. 8.3.3 Dechra Veterinary Products Companion Animal Pharmaceutical Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Dechra Veterinary Products Companion Animal Pharmaceutical Product Portfolio
  18. 8.3.5 Dechra Veterinary Products Recent Developments
  19. 8.4 Elanco Animal Health
  20. 8.4.1 Elanco Animal Health Company Information
  21. 8.4.2 Elanco Animal Health Business Overview
  22. 8.4.3 Elanco Animal Health Companion Animal Pharmaceutical Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Elanco Animal Health Companion Animal Pharmaceutical Product Portfolio
  24. 8.4.5 Elanco Animal Health Recent Developments
  25. 8.5 Meiji
  26. 8.5.1 Meiji Company Information
  27. 8.5.2 Meiji Business Overview
  28. 8.5.3 Meiji Companion Animal Pharmaceutical Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Meiji Companion Animal Pharmaceutical Product Portfolio
  30. 8.5.5 Meiji Recent Developments
  31. 8.6 Ouro Fino Saude
  32. 8.6.1 Ouro Fino Saude Company Information
  33. 8.6.2 Ouro Fino Saude Business Overview
  34. 8.6.3 Ouro Fino Saude Companion Animal Pharmaceutical Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Ouro Fino Saude Companion Animal Pharmaceutical Product Portfolio
  36. 8.6.5 Ouro Fino Saude Recent Developments
  37. 8.7 Parnell
  38. 8.7.1 Parnell Company Information
  39. 8.7.2 Parnell Business Overview
  40. 8.7.3 Parnell Companion Animal Pharmaceutical Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Parnell Companion Animal Pharmaceutical Product Portfolio
  42. 8.7.5 Parnell Recent Developments
  43. 8.8 Vetoquinol
  44. 8.8.1 Vetoquinol Company Information
  45. 8.8.2 Vetoquinol Business Overview
  46. 8.8.3 Vetoquinol Companion Animal Pharmaceutical Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Vetoquinol Companion Animal Pharmaceutical Product Portfolio
  48. 8.8.5 Vetoquinol Recent Developments
  49. 8.9 Virbac
  50. 8.9.1 Virbac Company Information
  51. 8.9.2 Virbac Business Overview
  52. 8.9.3 Virbac Companion Animal Pharmaceutical Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Virbac Companion Animal Pharmaceutical Product Portfolio
  54. 8.9.5 Virbac Recent Developments
  55. 8.10 Zoetis
  56. 8.10.1 Zoetis Company Information
  57. 8.10.2 Zoetis Business Overview
  58. 8.10.3 Zoetis Companion Animal Pharmaceutical Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Zoetis Companion Animal Pharmaceutical Product Portfolio
  60. 8.10.5 Zoetis Recent Developments
  61. 8.11 Bayer Animal Health
  62. 8.11.1 Bayer Animal Health Company Information
  63. 8.11.2 Bayer Animal Health Business Overview
  64. 8.11.3 Bayer Animal Health Companion Animal Pharmaceutical Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bayer Animal Health Companion Animal Pharmaceutical Product Portfolio
  66. 8.11.5 Bayer Animal Health Recent Developments
  67. 8.12 Merck Animal Health
  68. 8.12.1 Merck Animal Health Company Information
  69. 8.12.2 Merck Animal Health Business Overview
  70. 8.12.3 Merck Animal Health Companion Animal Pharmaceutical Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Merck Animal Health Companion Animal Pharmaceutical Product Portfolio
  72. 8.12.5 Merck Animal Health Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst